Skip to main content

The latest news &
insights from ArteraAI

View company news, research articles, publications, and industry thought leadership currently making headlines in the cancer treatment space.

All Categories
Media Coverage
Publications
Videos
Insights
Press Releases

All Categories

Media Coverage

Positioning & Distribution Will Determine the Winning Healthcare AI...

In a crowded healthcare AI market, the winners will be those that control key leverage points — where data is created, workfl [...]

Insights

Artera Product Webinar – August 2025

The ArteraAI Prostate Test is transforming the risk stratification landscape for treating prostate cancer. For lower-risk pat [...]

Videos

AI Tools Speed Prostate Cancer Decisions With Faster Results

FDA-authorized artificial intelligence (AI) tools have the potential to help patients with prostate cancer get clearer answer [...]

Media Coverage

Across the Prostate Cancer Continuum: Translating ArteraAI’s Biopsy Model...

Since launching the ArteraAI Prostate Test, Artera has used multimodal artificial intelligence (MMAI) algorithms to help thou [...]

Media Coverage

How Marc Benioff paired experts in AI and prostate...

The company was formed in September 2021 and two years later lined up $90 million.

Media Coverage

FDA just signed off on AI predicting long-term cancer...

The ArteraAI prostate test uses artificial intelligence and biomarkers to predict if standard hormone therapy will be effecti [...]

Media Coverage

FDA Okays AI-Based Prostate Cancer Risk-Stratification Tool

The US FDA has granted De Novo marketing authorization for ArteraAI Prostate (Artera, Los Altos, California), a novel artific [...]

Media Coverage

Identifying Patients Who Will Benefit From Intensified Prostate Cancer...

Identifying men with high-risk, non-metastatic prostate cancer who will truly benefit from intensified treatment from therape [...]

Load More